ChromaDex, a natural products company that provides proprietary, science-based solutions and ingredients for a variety of industries, has licensed from Green Molecular S.L. the exclusive worldwide patent rights pertaining to pharmaceutical and cosmetic preparations of pterostilbene for topical application for prevention and/or treatment of skin diseases, damage, or injuries, including those linked to aging and sun exposure.
Following this most recent acquisition, ChromaDex' patent portfolio consists of eight patents and patents pending relating to pterostilbene. This is the company's second acquisition made of worldwide patent rights for pTeroPure®, ChromaDex's branded nature identical form of pterostilbene, associated with skincare.
"We intend to continue our strategy to build intellectual property around our ingredients. By building a robust skincare IP portfolio, we are positioning to become a meaningful provider of patent protected innovative ingredient technologies to this growing multi-billion dollar market place," Frank Jaksch, founder and CEO of ChromaDex stated in the press release.
pTeroPure is an antioxidant found in blueberries. In September 2012, ChromaDex announced findings from a phase 2/3 trial demonstrating that pTeroPure significantly reduced blood pressure in adults. Along in addition to several other effects, pterostilbene has shown potential for supporting heart health, cognitive function, anti-aging, weight loss, and other metabolic disorders.
"I am excited to have this collaboration with ChromaDex. Pterostilbene, as well as its possible association with other structurally-related natural polyphenols, has multiple applications in," Dr. Jose M. Estrela, research director of Green Molecular, stated. "Working with ChromaDex will allow for pterostilbene's cosmetic and pharmaceutical applications in skin care and pathology to reach the market."
For more information, visit ChromaDex.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net